FCGR3A and neoplasm: The first product reaching the clinical stage is AFM13-NK by Affimed, i.e., non-engineered UCB-NK cells precomplexed with AFM13 tetravalent bispecific antibodies that target a TAA on the tumor cells and CD16a on the NΚ cells.